Objective
to compare the clinical outcomes of BP-SES (Firehawk biodegradable polymer sirolimus-eluting stent with one-third the drug dose of other DES) versus second generation DES for percutaneous treatment of coronary stenoses
Study
prospective, multicentre single blind randomised non-inferiority trial (margin 3.85%)
Population
patients with chronic or acute coronary syndromes
Endpoints
target lesion failure as cardiac death, MI or ischemia-driven target lesion revascularisation at 12 months
Conclusion
the low dose sirolimus-eluting stent is non-inferior to second-generation DES with regard to MACE at 1 year
Yeh et al. J Am Coll Cardiol. 2024; October 30 online
